Fosun's Luvometinib Gets NMPA Priority Review for Pediatric LCH
CompanyDrug

Fosun’s Luvometinib Gets NMPA Priority Review for Pediatric LCH

Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma
CompanyDeals

Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma

Otsuka's VOYXACT Wins FDA Accelerated Approval for IgAN, First APRIL Blocker
CompanyDrug

Otsuka’s VOYXACT Wins FDA Accelerated Approval for IgAN, First APRIL Blocker

Wuzhong Pharma Faces Mandatory Delisting After CSRC Violations
Company

Wuzhong Pharma Faces Mandatory Delisting After CSRC Violations

Novartis's Itvisma Wins FDA Approval as First Gene Therapy for SMA
CompanyDrug

Novartis’s Itvisma Wins FDA Approval as First Gene Therapy for SMA

Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First
CompanyDrug

Novo’s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First

Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low
CompanyDrug

Novo Nordisk’s Semaglutite Alzheimer’s Failure Sends Stock to 4-Year Low

Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific
CompanyDrug

Zelgen’s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific

Hengrui's Ivarmacitinib NDA Accepted for Non‑Radiographic Axial Spondyloarthritis
CompanyDrug

Hengrui’s Ivarmacitinib NDA Accepted for Non‑Radiographic Axial Spondyloarthritis

AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy
CompanyDrug

AstraZeneca’s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy

Qihan-Biotech's QT-019B Universal CAR-T Wins Implied NMPA Approval
CompanyDrug

Qihan-Biotech’s QT-019B Universal CAR-T Wins Implied NMPA Approval

Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC
CompanyDrug

Junshi’s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC